Abstract:Objective: To investigate the relationship between early-stage renal acute rejection(AR) and the level of Fractalkine in urine, explore the diagnostic and noninvasive monitoring value in early stage after transplantation by measurement of urine Fractalkine. Methods: Urine samples were examined from renal transplant patients between January 2006 and October 2009. A total of 155 patients were enrolled, including 49 with biopsy-proved AR, 58 patients with stable renal function and no abnormal histological findings, 10 patients with subclinical rejection in protocol biopsy, 9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urine samples were also collected from 40 healthy controls. Fractalkine was measured in urine samples using a commercial human Fractalkine enzyme-linked immunosorbent assay (ELISA) kit. Immunohistochemistry for Fractalkine expression was performed on biopsies from renal transplant patients with AR and non-AR. Results: Forty-nine patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with stable renal function and healthy controls[(429.1±56.1)vs (94.6±8.4), (84.5±8.9)ng/mmol creatine, both P<0.001]. Patients with AR excreted urinary Fractalkine at a significantly higher level than levels in patients with acute tubular necrosis and chronic allograft nephropathy[(429.1±56.1)vs(133.0±9.8), (183.0±18.9)ng/mmol creatine, both P<0.001]. Receiver operating characteristic(ROC)curve was constructed to determine the discriminatory power of Fractalkine levels for diagnosis of AR. The area under ROC curve was 0.920(95% CI: 0.875-0.969, P<0.001), which showed that Fractalkine was a suitable marker for the diagnosis of AR. At a cut-off point of 157.5 ng/mmol creatinine, the sensitivity was 83.7% and the specificity was 84.5% (P<0.001). The dynamic level of urinary Fractalkine in AR patients within 3 weeks after transplantation fluctuated above 300 ng/mmol creatine, which is remarkably higher than patients with stable renal function (below 200 ng/mmol creatinine). Conclusions: As a noninvasive monitoring method, Fractalkine in urine may be a new approach for detection of AR as well as useful to predict response to antirejection therapy. It has good sensitivity and specificity. Besides, measurement of Fractalkine in urine is a simple, inexpensive method for the routine clinical monitoring after kidney transplantation.

Acute Renal Allograft Rejection is Associated with Increased Levels of Vascular Endothelial Growth Factor in the Urine

Non-invasive detection of acute renal allograft rejection by measurement of vascular endothelial growth factor in urine.

Prediction of Subclinical Renal Allograft Rejection by Vascular Endothelial Growth Factor in Serum and Urine.

Urinary C-X-C Motif Chemokines 13 is a Noninvasive Biomarker of Antibody-Mediated Renal Allograft Rejection

[Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients with Acute Rejection by Measurement of Urine Fractalkine].

Association of Pre-Transplant Serum Level of Anti-Endothelial Cell Antibody with Acute Rejection in Kidney Transplant Recipients

Urinary Fractalkine is a Marker of Acute Rejection.

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Acute rejection episodic outcomes resulted from pre-transplant serum level of the soluble CD30 in kidney transplant recipients

Artificial Urinary Biomarkers for Early Diagnosis of Acute Renal Allograft Rejection

Understanding the acute rejection of renal allograft (video)

Impact of Acute Rejection Episodes on Long-Term Renal Allograft Survival

Pre-transplant Serum Concentrations of Anti-Endothelial Cell Antibody in Panel Reactive Antibody Negative Renal Recipients and Its Impact on Acute Rejection

Histological Isolated Endarteritis Benefits Glomerular Filtration Rate And Allograft Survival After Anti-Rejection Treatment

[Combined Assay of Soluble CD30 and Hepatocyte Growth Factor for Diagnosis of Acute Renal Allograft Rejection].

Assessment of Different Biomarkers Provides Valuable Diagnostic Standards in the Evaluation of the Risk of Acute Rejection.

Continuous monitoring of peripheral blood retinol blinding protein-4 in the early stage after renal transplantation

Non-Invasive Diagnosis for Acute Rejection Using Urinary mRNA Signature Reflecting Allograft Status in Kidney Transplantation

[Urinary Connective Tissue Growth Factor As a Biomarker Chronic Allograft Nephropathy in a Rat Model].

Serum Fractalkine and Interferon-Gamma Inducible Protein-10 Concentrations Are Early Detection Markers for Acute Renal Allograft Rejection